This is an automatically translated article.
Urispas has the main ingredient Flavoxate Hydrochloride, which belongs to the group of drugs against urinary tract spasms. Urispas drug is commonly used in relieving pain symptoms, stimulating urination, bed-wetting caused by bladder-urethral spasms. Thorough understanding of the ingredients, uses, doses and side effects of Urispas medicine will help patients improve the effectiveness of treatment.
1. What is Urispas?
Urispas medicine is made in 100 or 200mg tablets, with the main ingredients including:
Active ingredient: Flavoxate (in the form of Flavoxate Hydrochloride). Excipients: Calcium phosphate, Hypromellose, Magnesium stearate, Polyethylene glycol, Corn starch and Talc powder just enough for 1 tablet. Pharmacodynamics:
Active ingredient Flavoxate hydrochloride is a Flavon substance with direct antispasmodic effect on smooth muscle through inhibition of Phosphodiesterase, due to calcium antagonistic action. Flavoxate hydrochloride is effective on smooth muscle of the urinary tract, especially on the bladder, increasing bladder capacity in patients presenting with spasticity. In addition, Flavoxate hydrochloride has effects on the smooth muscle of the small intestine, uterus, gallbladder and seminal vesicles.
2. What are the effects of Urispas?
Urispas drug is indicated for the treatment of the following cases:
Nocturia, dysuria, urgency, urinary frequency, urinary incontinence in diseases of cystitis, urethritis-bladder triangle, pain bladder, prostatitis, urethritis, urethritis. Support in the treatment of antispasmodic in kidney stones, ureteral stones. As an aid in the antispasmodic treatment of spasmodic disorders of the urinary tract after catheterization, cystoscopy or sequelae of lower urinary tract surgery. Reduces genital spasms seen in dysmenorrhea, hypertonia or dyskinesia of the uterus, pelvic pain.
3. Contraindications of the drug Urispas:
Allergy, hypersensitivity to any component of the drug Urispas. History of allergy to other drugs containing Flavoxate hydrochloride. History of allergy to antispasmodics. The patient has a history of or is present with any of the following obstructions: pyloric or duodenal obstruction, intestinal or ileal obstruction, dysuria, gastrointestinal bleeding, lower urinary tract obstruction.
4. Dosage and usage of Urispas:
Note: Urispas should be taken with meals.
Adults or children ≥ 12 years old:
Recommended dose: Take 100-200mg/time x 3-4 times/day. Reduce daily dose depending on patient response. Children < 12 years old:
Urispas is not recommended.
5. Notes when using Urispas
Treatment with Urispas drug with high dose or prolonged, can cause side effects such as:
Digestive: Nausea, vomiting, dry mouth, stomach pain, constipation. Central nervous system: Dizziness, headache, mental confusion, difficulty concentrating, especially in the elderly, drowsiness, nervousness, agitation. Hematology: Leukopenia. Cardiovascular: Tachycardia and palpitations, palpitations Allergies: Urticaria and other dermatological diseases, eosinophilia and subcutaneous hemorrhage, severe may lead to hypersensitivity and anaphylaxis. Ophthalmology: Increased eye strain, blurred vision, dilated pupils, increased sensitivity of eyes to light. Kidneys: Difficulty urinating. The drug should be discontinued when detecting the above symptoms or other abnormalities after taking Urispas. Patients and relatives should promptly notify the treating doctor about the use of Urispas or go to the nearest hospital for timely treatment.
Note the use of Urispas in the following subjects:
Use caution when using Urispas in children under 12 years old, the elderly. People with a history of or are suffering from diseases such as coronary artery disease, congestive heart failure, tachycardia, glaucoma in angle-closure glaucoma. Do not use Urispas during exercise or vigorous physical activity as it may cause hypothermia. Pregnancy: The U.S. Food and Drug Administration (FDA) classifies Flavoxate Hydrochloride as Group B, a group with no evidence of risk during pregnancy. However, the use of Urispas in pregnant women should be carefully evaluated by the treating physician. Lactation: Current data do not indicate whether doses of Urispas are excreted in human milk. Therefore, caution should be exercised when Urispas is administered to a nursing woman. Drivers or machine operators may experience some effects such as dizziness, headache, mental confusion, difficulty concentrating... after using Urispas. Therefore, limit the use of Urispas before and during work.
6. Urispas . drug interactions
Interactions with other drugs:
The active ingredient Flavoxate hydrochloride in Urispas may reduce the concentration and effect of the central nervous system Acetylcholinesterase inhibitor, Secretin. The effect of Urispas may be enhanced by concomitant administration of anti-muscarinin drugs such as antihistamines, tricyclic antidepressants, Amantadine, Phenothiazines, antipsychotics and Monoamine Oxidase Inhibitors (MAOIs). Above is the necessary information about the composition, indications, dosage and unwanted side effects or notes when using Urispas. Patients should carefully read the instructions for use of Urispas, and consult the treating doctor before use.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
Reference sources: webmd.com, drugs.com
